Engxenyeni yokuqala ka-2022, ukuthunyelwa kwemikhiqizo yezempilo efana nemithi yaseKorea, imishini yezokwelapha kanye nezimonyo kufinyelele ezingeni eliphezulu kakhulu. Ama-reagents okuxilonga i-COVID-19 kanye nemijovo kukhulisa ukuthunyelwa kwemikhiqizo kwamanye amazwe.
Ngokusho kwe-Korea Health Industry Development Institute (KHIDI), ukuthunyelwa kwamanye amazwe kwale mboni kufinyelele ku-$13.35 billion engxenyeni yokuqala yalo nyaka. Leso sibalo sikhuphuke ngo-8.5% sisuka ku-$12.3 billion kwikota yonyaka odlule futhi kwaba umphumela omkhulu kakhulu wengxenye yonyaka. Siqophe ngaphezu kuka-$13.15 billion engxenyeni yesibili ka-2021.
Ngokwemboni, ukuthunyelwa kwemithi kwamanye amazwe kufinyelele ku-US$4.35 billion, kukhuphuke ngo-45.0% kusuka ku-US$3.0 billion esikhathini esifanayo ngo-2021. Ukuthunyelwa kwemishini yezokwelapha kufinyelele ku-USD4.93 billion, kukhuphuke ngo-5.2% unyaka nonyaka. Ngenxa yokuvalelwa eShayina, ukuthunyelwa kwezimonyo kwehle ngo-11.9% kwaya ku-$4.06 billion.
Ukukhula kokuthunyelwa kwemithi kwamanye amazwe kuqhutshwe yimithi ye-biopharmaceuticals kanye nemijovo. Ukuthunyelwa kwemithi ye-biopharmaceuticals kufinyelele ku-$1.68 billion, kanti ukuthunyelwa kwemithi ye-goma kufinyelele ku-$780 million. Kokubili kubiza u-56.4% wazo zonke izidakamizwa ezithunyelwa kwamanye amazwe. Ikakhulukazi, ukuthunyelwa kwemithi ye-goma kukhuphuke ngo-490.8% unyaka nonyaka ngenxa yokwanda kokuthunyelwa kwemithi ye-goma ngokumelene ne-COVID-19 ekhiqizwe ngaphansi kokukhiqizwa kwenkontileka.
Emkhakheni wamadivayisi ezokwelapha, ama-reagent okuxilonga athatha isabelo esikhulu kunazo zonke, afinyelela ku-$2.48 billion, okwenyuke ngo-2.8% kusukela esikhathini esifanayo ngo-2021. Ngaphezu kwalokho, ukuthunyelwa kwemishini yokuthwebula izithombe nge-ultrasound ($390 million), ama-implant ($340 million) kanye nemishini ye-X-ray ($330 million) kwaqhubeka nokukhula, ikakhulukazi e-US nase-China.
Isikhathi sokuthunyelwe: Agasti-23-2022